Titan Pharmaceuticals Announces Presentation of Probuphine

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Titan Pharmaceuticals Announces Presentation of Probuphine Phase 3 Data at American Society of Addiction Medicine Annual Conference

SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 15, 2016) -   Titan Pharmaceuticals, Inc. ( NASDAQ : TTNP ) announced today the presentation of data from the last Phase 3 study of Probuphine®, a six month subdermal buprenorphine implant for the long-term maintenance treatment of opioid addiction, at a poster session during the 47th Annual American Society of Addiction Medicine (ASAM) Annual Conference . The data indicates that participants who were clinically stable on sublingual buprenorphine at a dose of 8mg or less per day maintained stability when transferred to Probuphine, and that they were more likely to sustain abstinence from illicit opioids throughout the six months than participants who remained on sublingual buprenorphine. The Probuphine New Drug Application (NDA) is currently under review by the FDA with an action date of May 27, 2016.

"This was the first head-to-head comparison study of Probuphine and sublingual buprenorphine, demonstrating the efficacy of a long-acting six month buprenorphine implant," said co-lead investigator and an author of the presentation Richard N. Rosenthal, M.D., Professor of Psychiatry and Medical Director of Addiction Psychiatry at the Icahn School of Medicine at Mount Sinai. "The study results show that participants in the implant group sustained clinical stability over the course of six months. The implant group was also more likely to remain free from illicit opioids at 85.7% compared to 71.9% of those maintained on sublingual buprenorphine. If approved, Probuphine could help expand access to medication to treat opioid use disorders, providing people with a new option."

The poster titled, "A Randomized Trial of Probuphine Implants in Adults Stabilized on Sublingual Buprenorphine," presented data from the double-blind, double-dummy study, which was designed to determine the efficacy and safety of Probuphine as a maintenance treatment for opioid addiction. The primary endpoint was a non-inferiority comparison of the Probuphine and the sublingual buprenorphine treatment arms. As previously reported, the study met its primary endpoint as well as all secondary endpoints, and the treatment was well tolerated by the study subjects. Further details are included in the poster presentation, which was co-authored by Michelle R. Lofwall, M.D., University of Kentucky College of Medicine, Center on Drug and Alcohol Research in Lexington, Kentucky; Sonnie Kim, Ph.D., Braeburn Pharmaceuticals; Katherine L. Beebe, Ph.D., Titan Pharmaceuticals; Michael Chen, Ph.D., TCM Groups, Inc.; and Frank J. Vocci, Ph.D., Friends Research Institute.

"We are very pleased to be presenting these important data for the first time at the ASAM meeting and will continue to work closely with our partner, Braeburn Pharmaceuticals, on a broad medical communications strategy for Probuphine, if approved by the FDA," said Kate Beebe, Ph.D., Executive Vice President and Chief Development Officer of Titan Pharmaceuticals.

Probuphine was developed using Titan's proprietary platform technology, ProNeura™, a non-biodegradable drug delivery implant designed to provide continuous, long- term steady state levels of medication in the blood. In January 2016, the FDA reviewed the Probuphine NDA at a meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC), and following a discussion of the data presented, the committee voted 12-5 in favor of approval of Probuphine. If approved by the FDA, Probuphine would be the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single procedure.

About the ProNeura Long-term Drug Delivery Platform   ProNeura is Titan's proprietary, long-term drug delivery platform utilized in the development of products for the treatment of select chronic conditions that may benefit from the delivery of continuous, non-fluctuating levels of certain medications over an extended period of six months to a year. ProNeura consists of a small, solid rod made from a mixture of ethylene-vinyl acetate ("EVA") and a drug substance. The resulting product is a solid matrix that is placed subdermally, normally in the inner part of the upper arm, during a simple office procedure, and is removed in a similar manner at the end of treatment. The drug substance is released continuously through the process of dissolution, resulting in a stable, non-fluctuating blood level similar to that seen with intravenous administration. These long-term, linear-release characteristics are medically desirable to avoid the peak and trough swings from oral dosing that pose problems in the current treatments for many diseases, especially diseases of the central nervous system. Titan has issued patents as well as patent applications covering the use of the ProNeura long-term drug delivery platform for the formulation of specific products for the treatment of certain chronic diseases, such as opioid addiction, Parkinson's disease, and others.

About Titan Pharmaceuticals Titan Pharmaceuticals Inc. ( NASDAQ : TTNP ), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product candidate is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has granted U.S. and Canadian commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions, such as Parkinson's disease, where maintaining consistent blood levels of a therapeutic agent may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com .

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT: Titan Pharmaceuticals, Inc.: Sunil Bhonsle President (650) 244-4990 Investors: Stephen Kilmer (650) 989-2215 skilmer@titanpharm.com Media: Susan Thomas (650) 989-2216 sthomas@titanpharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 100

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 90

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 102

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 88

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 101

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 112

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 100

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading

Top 5 Most Recently Viewed Articles

La-Z-Boy Faces Major Stock Decline After Weak Earnings Report

Updated Category News Views 264

La-Z-Boy Stock Experiences Significant Drop La-Z-Boy Incorporated (NYSE: LZB) witnessed a dramatic 23.55% decline in after-hours trading, with shares plummeting from $39.11 to $29.90. This downturn followed the release of disappointing first-quarter results that did not meet analysts' expectations, prompting concerns about operational challenges. Disappointing Earnings...

Continue Reading
CLEAR Secure, Inc. Reveals Impressive Q3 2025 Performance

Updated Category News Views 224

CLEAR Secure, Inc.'s Q3 2025 Financial Overview CLEAR Secure, Inc. (NYSE: YOU), the leader in secure identity technologies, has recently unveiled its financial highlights for the third quarter of the 2025 fiscal year. As an innovative firm at the forefront of identity verification, CLEAR continues to address the growing needs in the security sector amid increasing cyber...

Continue Reading
Ameren Corporation Celebrates 10 Years of Disability Inclusion

Updated Category News Views 62

Ameren Corporation Champions Disability Inclusion Ameren Corporation (NYSE: AEE) has made impressive advancements in promoting disability inclusion, scoring a perfect 100 on the Disability Equality Index for the tenth year running. This recognition highlights Ameren’s role as a leader in fostering an inclusive workplace that values diversity and actively supports...

Continue Reading
Labcorp Faces Lawsuit: Wiretapping Accusations Surface

Updated Category News Views 60

Labcorp's Legal Tangle Unveiled One minute you're on Labcorp's website searching for medical info, the next you're caught up in a class-action legal whirlwind. Legal drama is not on any patient’s checklist, but here we are, with Labcorp knee-deep in some serious allegations. The crux of the matter points to alleged wiretapping violations, with claims that Labcorp,...

Continue Reading
Advent's $2.5 Billion Acquisition of Sapiens: A New Era Looms

Updated Category News Views 203

Advent to Acquire Sapiens for $2.5 Billion Sapiens International Corporation N.V. (NASDAQ: SPNS), a leader in software solutions for the insurance sector, has seen its stock price soar following the exciting announcement that it will be acquired by global private equity firm Advent. The all-cash acquisition deal is valued at approximately $2.5 billion, indicating a...

Continue Reading